BARDA Begins Stockpiling APIs For Critical Drugs
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.
You may also be interested in...
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.